A phase Ib/II trial assessed the efficacy of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated NSCLC who experienced disease progression while receiving first-generation EGFR inhibitors (gefitinib, n = 72; erlotinib, n = 30; and afatinib, n = 4) [124]. Here, EGFR is linked to non-small cell lung carcinoma.